Olplus Tablet

Adult dose

This drug is administered as one tablet once daily without regard to meals when blood pressure is not adequately controlled after dose adjustment of olmesartan medoxomil or hydrochlorothiazide alone. The dosage should be adjusted every 2 to 4 weeks considering the patient’s blood pressure response. For patients taking high doses of hydrochlorothiazide monotherapy or those with fluid depletion and hyponatremia, the hydrochlorothiazide dose should be reduced to 12.5 mg.

Child dose

Safety and efficacy in pediatric patients have not been established, thus use is not recommended.

This drug can cause serious harm or death to the fetus and newborn during the second and third trimesters of pregnancy, so it should be stopped immediately if pregnancy is confirmed. Patients who are allergic to any of the components of this drug or have hypersensitivity to certain diuretics, those with severe kidney or liver disease, pregnant or nursing mothers, and those with certain genetic metabolic disorders should not take this drug. Patients with decreased blood volume or weakened kidney function, those with liver disease, patients with certain heart diseases, the elderly, and infants need special care and close monitoring when using this drug. This drug lowers blood pressure, which may lead to dizziness or hypotension, so caution is advised when engaging in dangerous activities such as high-altitude work or driving. While taking this drug, electrolyte levels in the blood and kidney function should be regularly monitored for any abnormalities, with particular attention to potassium levels. This drug may interact with other antihypertensive medications, potassium supplements, certain diuretics, and anti-inflammatory analgesics, so patients should inform their healthcare provider of any other medications they are taking. During pregnancy or breastfeeding, it is advisable to avoid this medication or consult a doctor, particularly because adverse reactions may occur in breastfeeding infants. Safety and effectiveness in pediatric patients have not yet been established, so it is recommended not to administer to children. In case of overdose, symptoms such as hypotension, electrolyte imbalances, and dehydration may occur, and immediate medical attention is necessary. If new lesions on the skin appear, or symptoms such as eye pain, vision impairment, or difficulty breathing occur during treatment, the patient should inform their doctor immediately.

Serious side effects

Urticaria, severe swelling (edema), angioedema, anaphylactic reactions, serious allergic reactions, hives, severe skin adverse reactions (including severe rash, blisters, skin peeling, mucosal pain), difficulty breathing, respiratory distress, asthma attacks, acute respiratory distress syndrome (ARDS), liver abnormalities (jaundice, hepatitis, autoimmune hepatitis), severe neurological symptoms (headache, confusion, seizures not reported), acute renal failure,

Mild side effects

• Dizziness
• headache
• nausea
• vomiting
• diarrhea
• dyspepsia
• abdominal pain
• gastroenteritis
• chest pain
• back pain

This drug should be stored in a tightly closed container to prevent exposure to air or moisture. It is best to maintain a storage temperature between 1 degree and 25 degrees Celsius at room temperature. This helps to maintain the drug's effectiveness for a longer period.

Appearance

Light orange round film-coated tablets

Package unit

30 tablets/bottle, 300 tablets/bottle